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Summary
Background It has been suggested that inﬂ ammation status, as assessed by C-reactive protein (CRP) concentration, 
modiﬁ es the vascular protective eﬀ ects of statin therapy. In particular, there have been claims that statins might be 
more beneﬁ cial in people with raised CRP concentrations, and might even be ineﬀ ective in people with low 
concentrations of both CRP and LDL cholesterol. This study aimed to test this hypothesis. 
Methods In 69 UK hospitals, 20 536 men and women aged 40–80 years at high risk of vascular events were randomly 
assigned to simvastatin 40 mg daily versus matching placebo for a mean of 5·0 years. Patients were categorised into 
six baseline CRP groups (<1·25, 1·25–1·99, 2·00–2·99, 3·00–4·99, 5·00–7·99, and ≥8·00 mg/L). The primary 
endpoint for subgroup analyses was major vascular events, deﬁ ned as the composite of coronary death, myocardial 
infarction, stroke, or revascularisation. Analysis was by intention to treat. This study is registered, number 
ISRCTN48489393.
Findings Overall, allocation to simvastatin resulted in a signiﬁ cant 24% (95% CI 19–28) proportional reduction in the 
incidence of ﬁ rst major vascular event after randomisation (2033 [19·8%] allocated simvastatin vs 2585 [25·2%] 
allocated placebo). There was no evidence that the proportional reduction in this endpoint, or its components, varied 
with baseline CRP concentration (trend p=0·41). Even in participants with baseline CRP concentration less than 
1·25 mg/L, major vascular events were signiﬁ cantly reduced by 29% (99% CI 12–43, p<0·0001; 239 [14·1%] vs 
329 [19·4%]). No signiﬁ cant heterogeneity in the relative risk reduction was recorded between the four subgroups 
deﬁ ned by the combination of low or high baseline concentrations of LDL cholesterol and CRP (p=0·72). In particular, 
there was clear evidence of beneﬁ t in those with both low LDL cholesterol and low CRP (27% reduction, 99% CI 
11–40, p<0·0001; 295 [15·6%] vs 400 [20·9%]).
Interpretation Evidence from this large-scale randomised trial does not lend support to the hypothesis that baseline 
CRP concentration modiﬁ es the vascular beneﬁ ts of statin therapy materially.
Funding UK Medical Research Council, British Heart Foundation, Merck, Roche Vitamins, and GlaxoSmithKline.
Introduction
Inﬂ ammation is thought to contribute to the 
pathogenesis of coronary heart disease.1 C-reactive 
protein (CRP), an acute phase reactant synthesised by 
the liver, is the most extensively studied systemic marker 
of inﬂ ammation. Results from a meta-analysis2 of 
individual participant data from 54 prospective 
observational studies showed that CRP concentration 
was associated with the risk of coronary heart disease, 
ischaemic stroke, and vascular and non-vascular 
mortality. However, associations with ischaemic vascular 
diseases were explained largely by conventional risk 
factors (eg, CRP is positively correlated with smoking, 
diabetes, physical inactivity, blood pressure, body-mass 
index, non-HDL cholesterol, and triglycerides2), and so 
they might not reﬂ ect causality (which is supported by 
genetic-epidemiological studies3). Nonetheless, the 
ability of CRP to predict vascular risk means that it 
might still be useful as a biomarker to identify 
individuals who would particularly beneﬁ t from 
therapies to reduce risk.4
Some,5,6 but not all,7 subgroup analyses undertaken in 
previous randomised trials of statin therapy have suggested 
that the vascular beneﬁ ts might be greater in the presence 
of inﬂ ammation than in its absence. It has even been 
suggested that people who have low concentrations of both 
LDL cholesterol and CRP might not beneﬁ t much from 
statin therapy.8 The JUPITER trial9 randomly allocated 
17 802 apparently healthy men and women with LDL 
cholesterol concentrations less than 130 mg/L (3·4 mmol/L) 
but CRP concentrations 2·0 mg/L or greater to receive 
either rosuvastatin 20 mg daily or matching placebo. 
Allocation to rosuvastatin reduced LDL cholesterol at 1 year 
by about 50% (ie, 1·2 mmol/L) and CRP by about 40% 
(1·3 mg/L) and, during median treatment duration of about 
2 years, there was a signiﬁ cant 44% reduction in the primary 
composite endpoint of myocardial infarction, stroke, 
arterial revascularisation, admission to hospital for unstable 
angina, or death from cardiovascular causes.9 It has been 
suggested that this large relative risk reduction is greater 
than might have been expected given the achieved LDL 
cholesterol reduction,9,10 raising the possibility that the 
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beneﬁ ts of statins might be proportionally greater in people 
with high CRP concentrations. Secondary analyses of the 
JUPITER trial did not record any evidence that the eﬀ ect of 
rosuvastatin on vascular events diﬀ ered according to 
baseline CRP concentration,11 but these analyses included 
only three baseline groups for CRP (because of the relatively 
small number of events) and were not able to assess the 
eﬀ ect in people with CRP concentration less than 2·0 mg/L 
(because they were not eligible for the trial).
The Heart Protection Study (HPS) is, to date, the largest 
randomised trial of statin therapy and was undertaken in 
high-risk patients in whom large numbers of major 
vascular events occurred during the study treatment 
period. This study tested the hypothesis that the eﬀ ects of 
statin therapy diﬀ er according to baseline concentrations 
of CRP and LDL cholesterol. 
Methods
Study design and participants
Details of the objectives, design, and methods of HPS 
have been previously reported,12,13 and are summarised in 
this Article. Between 1994 and 1997, 20 536 men and 
women aged 40–80 years at high risk of vascular events 
were recruited from 69 UK hospitals. Participants had to 
have a previous diagnosis of coronary disease, occlusive 
disease of non-coronary arteries, diabetes (type 1 or 2), or, 
for men 65 years and older, be receiving drug treatment 
for hypertension. The exclusion criteria are listed in the 
study protocol. Ethics approval was obtained from 
relevant authorities.
At the initial screening visit, nurses recorded 
information about past medical history and other relevant 
factors; measured the patient’s height, weight, and blood 
pressure; and took a non-fasting blood sample. Potentially 
eligible patients were given information about the study 
and asked for their written agreement to participate. 
Consenting participants entered a run-in phase, consist-
ing of 4 weeks of placebo followed by 4–6 weeks of 40 mg 
simvastatin daily. Compliant individuals who did not 
have a major problem during the run-in and remained 
eligible were then randomised into the study and had 
their current medication recorded.
<1·25 mg/L 
(n=3397)
1·25–1·99 mg/L 
(n=2729)
2·00–2·99 mg/L 
(n=2943)
3·00–4·99 mg/L 
(n=3766)
5·00–7·99 mg/L 
(n=2562)
≥8·00 mg/L 
(n=3048)
Not measured 
(n=2091)
Log CRP (log mg/L) –0·3 (0·5) 0·5 (0·1) 0·9 (0·1) 1·3 (0·1) 1·8 (0·1) 2·7 (0·5) ..
Age (years) 62·6 (9·0) 63·8 (8·5) 64·1 (8·3) 64·4 (8·1) 64·2 (8·0) 64·3 (8·1) 64·7 (8·6)
Men 80·8% 79·2% 78·1% 76·6% 71·9% 68·6% 68·5%
Previous disease*
MI 42·4% 42·7% 44·1% 43·3% 42·7% 41·9% 29·0%
Other CHD without MI 23·4% 24·8% 24·6% 24·6% 23·0% 23·2% 21·8%
No CHD 34·2% 32·5% 31·3% 32·1% 34·3% 34·9% 49·2%
Cerebrovascular disease 14·2% 14·9% 15·2% 16·0% 16·2% 17·3% 18·9%
Peripheral vascular disease 22·9% 28·6% 30·4% 35·5% 39·0% 40·4% 34·8%
Diabetes 29·4% 27·3% 28·2% 27·8% 29·5% 28·8% 34·1%
Drug use*
ACE inhibitors 15·5% 17·8% 19·7% 20·2% 21·9% 21·1% 20·0%
β blockers 26·3% 26·9% 26·8% 26·0% 25·8% 23·0% 25·0%
Diuretics 15·8% 19·7% 23·9% 25·1% 29·9% 32·3% 25·3%
Any treatment for 
hypertension
34·3% 39·5% 41·0% 41·8% 44·2% 45·3% 43·8%
Aspirin 65·7% 66·3% 65·0% 64·5% 63·1% 60·9% 54·2%
Current cigarette smoker* 8·8% 10·2% 11·9% 14·7% 19·1% 20·0% 15·9%
Physical measurements*
SBP (mm Hg) 141·3 (23·1) 143·7 (23·0) 144·4 (23·0) 145·1 (23·0) 144·9 (23·0) 145·4 (23·0) 146·6 (23·0)
DBP (mm Hg) 80·0 (12·2) 81·2 (12·1) 81·1 (12·1) 81·9 (12·1) 81·6 (12·1) 81·3 (12·2) 83·0 (12·2)
BMI (kg/m2) 25·7 (4·2) 26·9 (4·2) 27·5 (4·2) 28·1 (4·2) 28·6 (4·2) 28·8 (4·2) 27·9 (4·2)
Non-fasting blood lipids*
LDL cholesterol (mmol/L) 3·22 (0·80) 3·32 (0·80) 3·36 (0·80) 3·43 (0·80) 3·46 (0·80) 3·39 (0·80) 3·38 (0·80)
HDL cholesterol (mmol/L) 1·16 (0·31) 1·09 (0·30) 1·06 (0·30) 1·03 (0·30) 1·01 (0·30) 1·00 (0·30) 1·05 (0·30)
Log triglycerides (log mmol/L) 0·39 (0·56) 0·53 (0·56) 0·60 (0·56) 0·64 (0·56) 0·66 (0·56) 0·59 (0·56) 0·58 (0·56)
Randomised to simvastatin 50·0% 50·1% 51·1% 49·2% 50·0% 49·7% 50·3%
Randomised to vitamins 49·7% 50·8% 50·7% 49·4% 50·4% 49·7% 49·6%
Data are mean (SD) or percentage of patients. CRP=C-reactive protein. MI=myocardial infarction. CHD=coronary heart disease. ACE=angiotensin-converting enzyme. SBP=systolic blood pressure. DBP=diastolic 
blood pressure. BMI=body-mass index. *Adjusted for age and sex diﬀ erences between groups. 
Table 1: Patient characteristics by baseline concentration of CRP
For more about the HPS 
protocol see http://www.
hpsinfo.org 
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Randomisation and masking
Participants were randomly assigned to receive 40 mg 
simvastatin daily or matching placebo (and, separately, 
with a factorial design, to receive antioxidant vitamins or 
matching placebo capsules14), and were followed up for a 
mean of 5·0 years. Randomisation was done centrally 
with use of a minimisation algorithm. Study outcomes 
were reported and coded in a masked manner.12
Procedures
Screening blood samples were cooled and sent by 
overnight courier to the coordinating centre laboratory 
for immediate separation and assay, and for long-term 
storage in liquid nitrogen. After an average of 4·6 years, 
non-fasting blood was collected from all participants 
during the ﬁ nal year of follow-up. Lipid fractions 
(including LDL cholesterol measured directly) at 
baseline and during follow-up were analysed as 
previously reported.13 CRP was measured with a high-
sensitivity assay with an Olympus CRP Latex OSR 6199 
(Olympus Diagnostics, Melville, NY, USA) in plasma 
samples collected and stored at baseline from all 
participants and during the ﬁ nal year from a subset of 
participants. Within-assay and between-assay coeﬃ  cients 
of variation were less than 5% for baseline measurements 
of LDL cholesterol and CRP (data not shown).
Participants were to be seen in the study clinics at 
regular intervals throughout follow-up (with non-attending 
patients followed up by telephone or through their family 
doctor). At every follow-up, information was recorded 
about any suspected myocardial infarction, stroke, vascular 
procedure, or other serious adverse event (including 
admission to hospital for any reason). Further details were 
sought from general practitioners about all reports that 
might relate to vascular events, cancers, or deaths, and 
from UK national registries about cancers and certiﬁ ed 
causes of death. The primary prespeciﬁ ed endpoint for 
subgroup analyses was major vascular events, which were 
deﬁ ned as major coronary events (ie, coronary death and 
non-fatal myocardial infarction), any stroke (fatal or non-
fatal), or coronary or non-coronary revascularisation. 
During the study, 20 469 participants (99·7%) had 
complete follow-up for both mortality and morbidity.
Statistical analysis
Patients were categorised into six baseline CRP groups 
(<1·25, 1·25–1·99, 2·00–2·99, 3·00–4·99, 5·00–7·99, 
and ≥8·00 mg/L), each including about 3000 patients 
(2091 participants did not have CRP measured at 
baseline). The eﬀ ects of allocation to simvastatin on the 
incidence of particular outcomes were analysed with 
log-rank methods both overall and separately within 
each CRP group (and for the group without values). 
χ² tests for linear trend in the proportional eﬀ ects of 
simvastatin across the six CRP groups were undertaken. 
Subgroup analyses of a previous trial8 had generated 
the hypothesis that statins might not have much eﬀ ect 
in people with baseline concentrations of LDL 
cholesterol and CRP that are both low (deﬁ ned by the 
median values in that trial: LDL cholesterol 
<3·86 mmol/L and CRP <1·6 mg/L). To test that 
hypothesis in HPS, log-rank analyses were undertaken 
n Change in mean concentration from baseline to ﬁ nal follow-up
Placebo Simvastatin Absolute diﬀ erence Percentage diﬀ erence Diﬀ erence in SDs*
Changes in LDL cholesterol (mmol/L)
All patients 2727 –0·19 (0·02) –1·04 (0·02) –0·85 (0·03) –25% –1·1
Baseline CRP (mg/L)
<1·25 539 –0·11 (0·05) –0·98 (0·04) –0·87 (0·07) –26% –1·1
1·25–1·99 429 –0·23 (0·06) –1·00 (0·06) –0·77 (0·08) –23% –1·0
2·00–2·99 460 –0·23 (0·06) –1·11 (0·05) –0·88 (0·08) –26% –1·1
3·00–4·99 547 –0·25 (0·06) –1·12 (0·05) –0·87 (0·07) –26% –1·1
5·00–7·99 377 –0·19 (0·07) –0·97 (0·06) –0·79 (0·09) –24% –1·0
≥8·00 375 –0·13 (0·08) –1·05 (0·06) –0·91 (0·10) –27% –1·1
Changes in log CRP (log mg/L)
All patients 2727 –0·04 (0·03) –0·36 (0·03) –0·32 (0·04) –27% –0·3
Baseline LDL cholesterol (mmol/L)†
<2·69 587 –0·08 (0·06) –0·37 (0·07) –0·30 (0·09) –26% –0·3
2·69–3·13 550 –0·05 (0·06) –0·35 (0·07) –0·30 (0·09) –26% –0·3
3·14–3·52 538 –0·09 (0·06) –0·44 (0·06) –0·35 (0·09) –30% –0·4
3·53–4·01 548 0·03 (0·06) –0·41 (0·06) –0·44 (0·09) –36% –0·4
≥4·02 504 –0·02 (0·07) –0·22 (0·06) –0·20 (0·09) –18% –0·2
Data in parentheses are SE. Final year follow-up sample was taken at a mean of 4·6 years. CRP=C-reactive protein. *SD at screening (0·80 mmol/L for LDL cholesterol; 
1·00 log mg/L for log CRP) in all 2727 people with data for concentrations of LDL cholesterol and CRP at baseline and ﬁ nal year of follow-up. †Separated into approximate 
ﬁ fths of the baseline distribution in all 20 536 randomised patients.
Table 2: Eﬀ ect of simvastatin allocation on changes in concentrations of LDL cholesterol and CRP between baseline and ﬁ nal year of follow-up
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of the eﬀ ect of allocation to simvastatin on major 
vascular events in the four groups that were deﬁ ned 
jointly by the same median concentrations of LDL 
cholesterol and CRP. To make some allowance for 
multiple comparisons, only summary rate ratios or 
reductions are presented with 95% CIs, whereas those 
for subgroup analyses are presented with 99% CIs. All 
statistical tests were two-sided and done on an intention-
to-treat basis.
This study is registered, number ISRCTN48489393.
Role of the funding source
The sponsors of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. All members of the Writing 
Committee agreed to submit the paper for publication. 
JE, DB, and SP had full access to all the data in the study.
Results
Baseline CRP concentration was substantially skewed 
(skewness coeﬃ  cient 5·9), with a median of 3·07 mg/L 
(IQR 1·59–5·85). Table 1 shows the patient charac-
teristics for each baseline CRP group. In this selected 
trial population, participants with higher baseline CRP 
concentrations were more likely to be women, to have 
had a diagnosis of peripheral vascular disease, to be 
taking diuretic drugs, and to be a current smoker than 
were those with lower baseline CRP concentrations 
(table 1). Participants with high baseline CRP 
concentrations had higher mean body-mass index, LDL 
cholesterol, and triglyceride concentration, and lower 
mean HDL cholesterol concentration (although the 
age-adjusted and sex-adjusted correlation between LDL 
cholesterol and log CRP concentration was 
weak; r=0·08).
Figure 1: Eﬀ ect of simvastatin allocation on vascular events by baseline concentration of C-reactive protein
Simvastatin Event rate ratio 
(95% or 99% CI)(n=10 269)
Major vascular event
<1·25 mg/L 239 (14·1%) 329 (19·4%)
1·25–1·99  mg/L 263 (19·2%) 328 (24·1%)
2·00–2·99  mg/L 292 (19·4%) 341 (23·7%)
3·00–4·99  mg/L 366 (19·8%) 506 (26·5%)
5·00–7·99 mg/L 294 (23·0%) 376 (29·3%)
≥8·00 mg/L 387 (25·6%) 469 (30·6%)
Missing 192 (18·3%) 236 (22·7%)
Total  2033 (19·8%) 2585 (25·2%)                    0·76 (0·72–0·81)
χ21=0·7, p for trend=0·41
Major coronary event
<1·25 mg/L 106 (6·2%) 149 (8·8%)
1·25–1·99  mg/L 123 (9·0%) 144 (10·6%)
2·00–2·99  mg/L 135 (9·0%) 155 (10·8%)
3·00–4·99  mg/L 154 (8·3%) 246 (12·9%)
5·00–7·99 mg/L 126 (9·8%) 171 (13·3%)
≥8·00 mg/L 181 (12·0%) 237 (15·4%)
Missing 73 (6·9%) 110 (10·6%)
Total  898 (8·7%) 1212 (11·8%)             0·73 (0·67–0·79)
χ21=0·1, p for trend=0·81
Stroke
<1·25 mg/L 39 (2·3%) 72 (4·2%)
1·25–1·99  mg/L 59 (4·3%) 67 (4·9%)
2·00–2·99  mg/L 55 (3·7%) 69 (4·8%)
3·00–4·99  mg/L 76 (4·1%) 113 (5·9%)
5·00–7·99 mg/L 73 (5·7%) 98 (7·6%)
≥8·00 mg/L 87 (5·7%) 106 (6·9%)
Missing 55 (5·2%) 60 (5·8%)
Total  444 (4·3%) 585 (5·7%)              0·75 (0·66–0·85)
χ21=1·1, p for trend=0·29
Revascularisation
<1·25 mg/L 115 (6·8%) 161 (9·5%)
1·25–1·99  mg/L 119 (8·7%) 164 (12·0%)
2·00–2·99  mg/L 133 (8·8%) 171 (11·9%)
3·00–4·99  mg/L 178 (9·6%) 225 (11·8%)
5·00–7·99 mg/L 143 (11·2%) 177 (13·8%)
≥8·00 mg/L 171 (11·3%) 203 (13·2%)
Missing 80 (7·6%) 104 (10·0%)
Total  939 (9·1%) 1205 (11·7%)             0·76 (0·70–0·83)
χ21=1·8, p for trend=0·18
(n=10 267)
Placebo
Simvastatin better
99% Cl or     95% CI
Placebo better
10·80·4 0·6 1·2 1·4 1·6
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As previously reported,12 allocation to simvastatin 
produced a mean diﬀ erence in LDL cholesterol between 
randomised groups during the trial of 1·0 mmol/L. In 
the selected subset of 2727 patients with LDL cholesterol 
and CRP measured at both screening and during the 
ﬁ nal year of follow-up, allocation to simvastatin 
produced a mean diﬀ erence between randomised 
groups of 0·85 mmol/L (SE 0·03 mmol/L) in LDL 
cholesterol, which is a 25% mean proportional 
reduction, and of 0·32 log mg/L (SE 0·04 log mg/L) in 
log CRP, which is a 27% mean proportional reduction 
(both p<0·0001; table 2). These diﬀ erences represented 
SD changes of 1·1 for LDL cholesterol and 0·3 for log 
CRP; thus, the reduction in relation to overall variability 
was much greater for LDL cholesterol than for CRP. 
The estimated changes in LDL cholesterol did not diﬀ er 
signiﬁ cantly by baseline CRP concentration, and nor 
did the estimated changes in CRP diﬀ er signiﬁ cantly by 
baseline LDL cholesterol (table 2; age-adjusted and sex-
adjusted correlation between changes in LDL cholesterol 
and changes in log CRP=0·14).
Overall, allocation to simvastatin produced a 
signiﬁ cant 24% (95% CI 19–28) proportional reduction 
in the incidence of ﬁ rst major vascular event after 
randomisation.12 There was no signiﬁ cant trend in the 
proportional risk reduction with increasing baseline 
CRP (ﬁ gure 1), with signiﬁ cant reductions in each of 
the baseline CRP groups, including in participants with 
CRP concentration less than 1·25 mg/L (29% risk 
reduction, 99% CI 12–43; p<0·0001). Indeed, even in 
those with baseline CRP concentration less than 1 mg/L, 
there was a signiﬁ cant 27% (99% CI 5–44) reduction in 
risk (166 [13·7%] allocated to simvastatin vs 218 [18·3%] 
allocated to placebo; p=0·0022).
Allocation to simvastatin reduced the incidence of ﬁ rst 
major coronary event by 27% (95% CI 21–33), of ﬁ rst 
stroke by 25% (15–34), and of ﬁ rst revascularisation by 
24% (17–30), with no signiﬁ cant trend in the proportional 
risk reduction with increasing baseline CRP concentration 
for any of these outcomes (ﬁ gure 1). There was also no 
signiﬁ cant trend in the proportional reduction in vascular 
death with increasing baseline CRP (ﬁ gure 2). Although 
a marginally signiﬁ cant trend in the proportional 
reduction in non-vascular mortality was noted with 
increasing CRP concentration (ﬁ gure 2), this result was 
not signiﬁ cant after taking into account the number of 
trend tests done (Bonferroni corrected p=0·10).
To test the hypothesis that the proportional eﬀ ect of 
statin therapy on vascular events might diﬀ er according 
to whether individuals have greater than mean 
concentrations of LDL cholesterol, CRP, both, or neither,8 
participants were categorised into four groups deﬁ ned by 
the median concentrations of LDL cholesterol 
(3·86 mmol/L) and CRP (1·6 mg/L) in the trial that 
generated the hypothesis. In HPS, there was no 
signiﬁ cant heterogeneity in the proportional reduction in 
major vascular events between these four groups 
(ﬁ gure 3). In particular, the proportional risk reduction 
in participants with low LDL cholesterol and low CRP 
(27%, 99% CI 11–40; p<0·0001) was statistically similar to 
that in participants with high LDL cholesterol and high 
CRP (23%, 10–35; p<0·0001). Even when the threshold 
used to deﬁ ne low LDL cholesterol was reduced to 
2·8 mmol/L (which was the median baseline 
concentration in the JUPITER trial9), the proportional 
reduction in major vascular events in participants with 
low LDL cholesterol and low CRP (92 [13·6%] vs 
128 [18·2%]; risk reduction 0·73, 99% CI 0·52–1·04; 
Figure 2: Eﬀ ect of simvastatin allocation on vascular and non-vascular death by concentration of baseline C-reactive protein
Vascular death
<1·25 mg/L 80 (4·7%) 106 (6·2%)
1·25–1·99  mg/L 89 (6·5%) 96 (7·1%)
2·00–2·99  mg/L 110 (7·3%) 112 (7·8%)
3·00–4·99  mg/L 150 (8·1%) 197 (10·3%)
5·00–7·99 mg/L 105 (8·2%) 141 (11·0%)
≥8·00 mg/L 178 (11·8%) 193 (12·6%)
Missing 69 (6·6%) 92 (8·8%)
Total  781 (7·6%) 937 (9·1%)         0·83 (0·75–0·91)
χ21=0·2, p for trend=0·65
Non-vascular death
<1·25 mg/L 72 (4·2%) 54 (3·2%)
1·25–1·99  mg/L 61 (4·5%) 57 (4·2%)
2·00–2·99  mg/L 69 (4·6%) 66 (4·6%)
3·00–4·99  mg/L 96 (5·2%) 108 (5·6%)
5·00–7·99 mg/L 82 (6·4%) 79 (6·2%)
≥8·00 mg/L 116 (7·7%) 149 (9·7%)
Missing 51 (4·9%) 57 (5·5%)
Total  547 (5·3%) 570 (5·6%)         0·95 (0·85–1·07)
χ21=5·7, p for trend=0·0166
Simvastatin Event rate ratio 
(95% or 99% CI)(n=10 269) (n=10 267)
Placebo
Simvastatin better
99% Cl or      95% CI
Placebo better
10·80·4 0·6 1·2 1·4 1·6
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p=0·0213) was still similar to the reduction recorded 
overall (ﬁ gure 3).
Discussion
In this study of more than 20 000 people at high risk of 
vascular events, 5·0 years of statin therapy reduced the 
risk of a major vascular event by a quarter, but there 
was no indication that the proportional risk reduction 
was larger in those with higher baseline CRP 
concentration. Indeed, even in participants with 
baseline CRP concentration less than 1·25 mg/L, or 
with low baseline concentrations of both LDL cholesterol 
and CRP, there were signiﬁ cant reductions in the risks 
of major vascular events. Furthermore, the proportional 
reduction in major vascular events in HPS did not 
diﬀ er signiﬁ cantly between participants with diﬀ erent 
baseline concentrations of other circulating inﬂ am-
matory markers, such as lipoprotein-associated phos-
pholipase A2 (a pro-inﬂ ammatory enzyme expressed in 
rupture-prone atherosclerotic plaque)15 or albumin (a 
liver-derived negative acute-phase reactant; results 
available on request). Hence, the present hypothesis-
testing analysis (which is based on large numbers of 
major vascular events) does not lend support to the 
suggestion from hypothesis-generating studies (which 
include far fewer vascular events) that the beneﬁ cial 
eﬀ ects of statin therapy are aﬀ ected by baseline CRP 
concentration or, more generally, by inﬂ ammation 
status (panel).
The proportional reduction in the risk of major 
vascular events with statin therapy seems to be directly 
related to the absolute reduction in LDL cholesterol that 
is achieved.16–18 A meta-analysis17 of 25 large randomised 
trials (including more than 150 000 participants) 
estimated that 80–90% of the heterogeneity between 
their results could be explained by diﬀ erences in the 
reduction of LDL cholesterol (87% for major coronary 
events and 84% for major vascular events), which 
contrasts with other interpretations from selected 
trials.8,19 In addition to the lipid-mediated eﬀ ects of 
statins, substantial interest has been generated in the 
possibility of lipid-independent pleiotropic eﬀ ects, 
perhaps by stabilisation of plaques through various anti-
inﬂ ammatory mechanisms.20,21
In apparent support of this hypothesis, analyses within 
some trials have shown that participants who achieve low 
CRP concentration on statin therapy, irrespective of their 
achieved LDL cholesterol concentration, have lower 
coronary event rates than do those who do not achieve 
low CRP.22,23 However, such comparisons of outcome in 
participants allocated to statins who achieve particular 
CRP concentrations and in those who do not versus the 
outcome in all of the participants allocated to placebo 
combined (irrespective of whether or not they would have 
achieved those CRP concentrations if they had been 
given statin therapy) are not randomised and, hence, 
prone to bias. For example, the observed risk diﬀ erences 
could be attributable to inherent diﬀ erences between the 
types of participant who achieve such CRP concentrations 
and those who do not, rather than diﬀ erences that are 
really due to the CRP reductions.24,25 Moreover, investi-
gators of a meta-analysis26 of 23 placebo-controlled trials 
have reported that at least 90% of the CRP reduction 
detected with therapies to lower LDL cholesterol (mostly 
statins) can be explained by reductions in LDL cholesterol. 
Because the proportional reduction in vascular events 
associated with the reduction in LDL cholesterol achieved 
in the JUPITER trial9 was larger than was expected from 
previous statin trials,16 it has been suggested that it 
provides support for non-lipid beneﬁ ts of statins. But, 
JUPITER was terminated early because of the emergence 
of clear evidence of beneﬁ t, so the size of the real eﬀ ects 
of treatment might well have been overestimated.27
The present hypothesis-testing analysis has several 
strengths. First, HPS has larger numbers of major 
vascular events than any other randomised trial of statin 
therapy, so it has greater statistical power to detect 
diﬀ erences in eﬀ ect size in diﬀ erent subgroups. Second, 
it can assess the eﬀ ects of statin therapy across a wide 
range of baseline concentrations of CRP or LDL 
cholesterol because participants were recruited with no 
constraints on the values of these factors. Third, the 
results are applicable not only to the wide range of people 
with pre-existing vascular disease who were recruited 
Figure 3: Eﬀ ect of simvastatin allocation on ﬁ rst major vascular event during follow-up by baseline concentrations of LDL cholesterol and CRP
Test for heterogeneity between four groups, excluding participants with missing data for baseline CRP concentration. Threshold values used to deﬁ ne low and high 
concentrations of LDL cholesterol and CRP are from the median values in the hypothesis-generating trial.8 CRP=C-reactive protein.
Median LDL 
cholesterol
(mmol/L)
Event rate ratio 
(95% or 99% CI)
LDL cholesterol <3·86 mmol/L; CRP <1·6 mg/L 3·0 1·0 295/1890 (15·6%) 400/1912 (20·9%)
LDL cholesterol <3·86 mmol/L; CRP ≥1·6 mg/L 3·1 4·1 1042/4997 (20·9%) 1318/5037 (26·2%)
LDL cholesterol ≥3·86 mmol/L; CRP <1·6 mg/L 4·2 1·0 68/455 (14·9%) 102/461 (22·1%)
LDL cholesterol ≥3·86 mmol/L; CRP ≥1·6 mg/L 4·3 4·4 436/1875 (23·3%) 529/1817 (29·1%)
Missing CRP 3·3 ·· 192/1052 (18·3%) 236/1040 (22·7%)
Total    2033/10 269 (19·8%) 2585/10 267 (25·2%) 0·76 (0·72–0·81)
χ23=1·3, p for heterogeneity=0·72
Median
CRP
(mg/L)
Simvastatin
(n=10 269)
Placebo
(n=10 267)
Simvastatin better
99% CI or    95% CI
Placebo better
10·80·4 0·6 1·2 1·4
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into HPS, but also to people without known vascular 
disease (as in JUPITER), since the proportional beneﬁ ts 
of statins are as large in primary prevention.16,18 In this 
respect, it is worth noting that people who have events 
during only a few years of treatment (eg, average time to 
events in a 4-year trial is only about 2 years) are most 
likely to have had pre-existing vascular disease, 
irrespective of whether they were derived from high-risk 
secondary prevention or low-risk primary prevention 
populations.
Because patients in the hypothesis-generating trials 
were allocated to pravastatin and lovastatin, and in 
JUPITER to rosuvastatin, the results from HPS, which 
studied simvastatin, might not necessarily be generalisable 
to other statins.28 But, the diﬀ erential eﬀ ect of diﬀ erent 
statins on the risk of major vascular events can be largely, 
if not wholly, explained by diﬀ erences in reduction in LDL 
cholesterol.16–18 Moreover, the 27% mean CRP reduction in 
HPS that was associated with a 0·85 mmol/L reduction 
in LDL cholesterol in participants allocated to simvastatin 
(table 2) is about the same per mmol/L LDL cholesterol 
reduction as the 37% mean CRP reduction in JUPITER, 
which was associated with a 1·2 mmol/L reduction in 
LDL cholesterol in those allocated to rosuvastatin.9 In the 
CORONA trial,6 rosuvastatin seemed to produce beneﬁ cial 
eﬀ ects on vascular events in patients with baseline CRP 
greater than 2 mg/L and not in those with lower 
concentrations. But, those analyses were retrospective 
and based on small numbers of events in people with 
CRP concentration less than 2 mg/L, so they might be 
indicative of data-dependent emphasis and chance.6 
Baseline CRP concentration did not seem to modify the 
eﬀ ects of rosuvastatin in JUPITER (although people with 
CRP <2 mg/L were excluded from this trial and it could 
only consider three CRP groups because of the relatively 
small number of events),11 or the eﬀ ects of diﬀ erent doses 
of simvastatin in the A to Z trial7 (albeit with very limited 
statistical power). Consequently, the ﬁ ndings in HPS, that 
reducing LDL cholesterol with simvastatin reduces the 
risk of major vascular events to a similar extent irrespective 
of presenting CRP concentrations (including among 
individuals with low concentrations of both CRP and 
LDL cholesterol), are probably broadly generalisable to 
other statins.
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